|
ATM P292L
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM P292L (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
ATM D2625_A2626delinsEP
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM D2625_A2626delinsEP (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
ATM E2039K
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM E2039K (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
CHEK2 G151S
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including CHEK2 G151S (PMID: 42223064; NCT04821622).
|
detail...
detail...
42223064
|
|
ATM R2032K
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R2032K (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
ATM A2067D
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM A2067D (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
CHEK2 inact mut
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including CHEK2 rearrangement, copy number loss, nonsense, frameshift, or splice site variants (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
ATM F2827C
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM F2827C (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
ATM R2547_S2549del
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R2547_S2549del (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
ATM D2708N
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM D2708N (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
RAD51C L219S
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including RAD51C L219S (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
ATM R2832C
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R2832C (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
RAD51C inact mut
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) and Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including RAD51C rearrangement, copy number loss, nonsense, frameshift, or splice site variants (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
ATR inact mut
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATR rearrangement, copy number loss, nonsense, frameshift, or splice site variants (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
CHEK2 R117G
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including CHEK2 R117G (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
CHEK2 A392V
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including CHEK2 A392V (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
MLH1 R265C
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including MLH1 R265C (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
CHEK2 K373E
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including CHEK2 K373E (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
ATM A2524P
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM A2524P (PMID: 42223064; NCT04821622).
|
detail...
detail...
42223064
|
|
ATM V2716A
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM V2716A (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
ATM V2662D
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM V2662D (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
ATM R3008C
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R3008C (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
ATM R3008H
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R3008H (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
ATM D2913Y
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM D2913Y (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
MLH1 inact mut
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including MLH1 rearrangement, copy number loss, nonsense, frameshift, or splice site variants (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
ATM R2227C
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R2227C (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
ATM Y2470D
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM Y2470D (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|
|
ATM S2855_V2856delinsRI
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM S2855_V2856delinsRI (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
ATM D2016G
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM D2016G (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
ATM inact mut
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM rearrangement, copy number loss, nonsense, frameshift, or splice site variants (PMID: 42223064; NCT04821622).
|
detail...
detail...
42223064
|
|
ATM A2622V
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM A2622V (PMID: 42223064; NCT04821622).
|
detail...
42223064
detail...
|
|
ATM G2765S
|
prostate cancer
|
sensitive
|
Enzalutamide + Talazoparib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM G2765S (PMID: 42223064; NCT04821622).
|
42223064
detail...
detail...
|